TH177974A - Pharmaceutical components for oral administration - Google Patents
Pharmaceutical components for oral administrationInfo
- Publication number
- TH177974A TH177974A TH1701006426A TH1701006426A TH177974A TH 177974 A TH177974 A TH 177974A TH 1701006426 A TH1701006426 A TH 1701006426A TH 1701006426 A TH1701006426 A TH 1701006426A TH 177974 A TH177974 A TH 177974A
- Authority
- TH
- Thailand
- Prior art keywords
- oral administration
- page
- pharmaceutical
- drug
- solubility
- Prior art date
Links
- 239000005426 pharmaceutical component Substances 0.000 title claims 3
- 239000001913 cellulose Substances 0.000 claims abstract 4
- 229920002678 cellulose Polymers 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 4
- 229940079593 drugs Drugs 0.000 claims abstract 4
- 239000002253 acid Substances 0.000 claims abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 239000011780 sodium chloride Substances 0.000 claims abstract 3
- 239000000126 substance Substances 0.000 claims abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 2
- 239000000470 constituent Substances 0.000 claims abstract 2
- 230000001419 dependent Effects 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical group N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 239000000306 component Substances 0.000 claims 1
- -1 hydroxypropyl Chemical group 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
Abstract
หน้า 1 ของจำนวน 1 หน้า บทสรุปการประดิษฐ์ การประดิษฐ์นี้เปิดเผยองค์ประกอบทางเภสัชกรรมสำหรับให้ทางปากที่ประกอบรามด้วย กรด 1 - {5-[(5-{[(2R)-2-เอทิลพีร์โรลิดิน-1-อิล]เมทิล}-4-[4-เมทอกซี-3-(ไตรฟลูออโรเมทิล)เฟนิล]- 1,3-ไทอะโซล-2-อิล)คาร์บาโมอิล]ไพราซิน-2-อิล}ไพเพอริดีน-4-คาร์บอกซิลิก ซึ่งเป็นสารประกอบ ที่มีสภาพละลายได้ที่ขึ้นกับ pH หรือเกลือซึ่งเป็นที่ยอมรับทางเภสัชกรรมของสารดังกล่าว และ อนุพันธ์เซลลูโลส ในองค์ประกอบทางเภสัชกรรมสำหรับให้ทางปากมีการปรับปรุงสภาพละลายได้ และสภาพดูดซึมได้ของยา สิทธิบัตรยา 1 page of the number 1 page summary of the invention The invention discloses the pharmaceutical constituents for oral administration of ram-containing acid 1 - {5 - [(5 - {[(2R) -2-ethyl perrolidin-1-il] methyl} -4-. [4-methoxy-3- (trifluoromethyl) phenyl] - 1,3-thiazole-2-il) carbamoyl] pyracin-2-il } Piperidine-4-carboxylic Which is compound With a pH-dependent solubility or a chemically acceptable salt of such substances and cellulose derivatives. In the pharmaceutical composition for oral administration, solubility is improved. And the absorbable condition of the drug, the patent of the drug
Claims (3)
Publications (1)
Publication Number | Publication Date |
---|---|
TH177974A true TH177974A (en) | 2018-07-12 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201490014A1 (en) | MODIFIED 4-METHYL-3 - [[4- (3-PYRIDINIL) -2-PYRIMIDINYL] AMINO] -N- [5- (4-METHYL-1H-IMIDAZOL-1-IL) -3- (TRIFTOROMETHYL) FENYL ISOLATED ] BENZAMIDE, SILUBILIZED WITH THE USE OF ORGANIC ACIDS | |
RU2018126158A (en) | APPLICATION OF TRIACETHYL-3-HYDROXYPHENYLENADENOSINE FOR THE PRODUCTION OF A PHARMACEUTICAL MEDICINE FOR THE PREVENTION OR TREATMENT OF A NON-ALCOHOLIC LIVER LIVER DISEASE DISEASE | |
PH12017501831A1 (en) | Pharmaceutical compositions for oral administration | |
EA200800947A1 (en) | NEW DERIVATIVES OF BENZIMIDAZOLES AND BENZOTIAZOLES, METHODS FOR CLEANING THEM, THEIR APPLICATION AS A MEDICINE, PHARMACEUTICAL COMPOSITIONS AND A NEW APPLICATION, IN PARTICULAR, IN QUALITY, INSERTS, INSERTS, INSPECTIONS, INSPECTIONS AND NEW APPLICATIONS, IN PARTICULAR, IN QUALITY. | |
TH177974A (en) | Pharmaceutical components for oral administration | |
TH1901000892A (en) | Dosage form for oral administration of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino) ]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-il-amino]-propionic acid sydethyl esters and their salts | |
TH1701007888A (en) | Stable pharmaceutical constituents for oral administration. | |
TH1901000460A (en) | Formulations that improve the pH-dependent release characteristics that contain azomeprazole or its salts are pharmaceutically accepted. | |
TH1601007447A (en) | Descent pressin, which is stabilized | |
TH177973A (en) | Stabilized pharmaceutical constituents | |
TH79585A (en) | Pharmaceutical components | |
TH178555A (en) | Heteroerril derivatives Or its pharmaceutical acceptable salt, method of preparation, and pharmaceutical constituents for the prevention or treatment of disease. Associated with PI3 kinase, which has the same thing as active ingredient. | |
TH1801003301A (en) | The accompanying pharmaceutical constituents include potent URAT1 inhibitors. | |
TH1801006015A (en) | Compound capsule preparation containing tadalafil and tamsulosin. And has better stability and elution rate | |
TH1601001257A (en) | Oral tablet composition containing corticosteroid for esophagitis caused by eosinophil | |
TH142629A (en) | The use of production binders provide storage stability for formulations. | |
TH1701002348A (en) | Coated beads containing CNS stimulants | |
TH147834A (en) | Internal parasite protection | |
TH91885A (en) | New concomitant dosage forms | |
TH182678A (en) | Tetrahydroquinoline derivatives, bromodomain inhibitors | |
TH1801004591A (en) | A complex preparation for oral administration containing Fat-soluble drugs And ready-made potions in solid form coated with oil repellent material | |
TH126521A (en) | A pharmaceutical formulation in a two-layer tablet formulation that includes: HMG-COA Reductase Inhibitor and Urbesar Tan | |
TH181225A (en) | ||
TH170460B (en) | "Pharmaceutical composition for oral administration, including tagane" | |
TH1701003202A (en) | Dosage Schedules for Agonists Selected Active to S1P1 Receptors |